Trial outcomes comparing cytokine agents for PBSC mobilization in autologous hematopoietic transplant patients have been controversial. We performed a systematic review and meta-analysis of evidence available on pegfilgrastim vs filgrastim in chemocytokine mobilization. Electronic literature searches of PubMed, EMBASE and CENTRAL identified nine articles eligible for qualitative analysis with one randomized controlled trial. Eight articles involving 719 patients were included in the meta-analysis. Results showed similar CD34+ cell collection yields for pegfilgrastim and filgrastim (SDM − 0.08, 95% CI: − 0.388 to 0.228). On comparison with filgrastim, pegfilgrastim showed a significantly earlier apheresis onset time (SDM: − 0.512, 95% CI: − 0.973 to − 0.050) and reduction in required apheresis procedures (SDM − 0.260, 95% CI: − 0.466 to − 0.054). Times to leukocyte (⩾1.0 × 10 9 /L) and platelet (⩾20 × 10 9 /L) recovery were similar between groups (SDM: 0.015, 95% CI: − 0.41 to 0.44 and SDM: 0.309, 95% CI: − 0.11 to 0.72, respectively). Both agents were well tolerated and mild bone pain was the most frequently reported adverse event. Pegfilgrastim may be a convenient alternative to filgrastim in PBSC mobilization for multiple myeloma and lymphoma patients, but further studies are required to clarify effects of cytokine dosage and previous cytotoxic exposure in specific subpopulations.
INTRODUCTION
High-dose chemotherapy followed by autologous hematopoietic SCT (auto-HSCT) is commonly employed in the treatment of hematologic malignancies including multiple myeloma and lymphomas. Although hematopoietic stem cells may be collected from either the BM or peripheral blood, transplantation with PBSCs is preferred considering the more efficient and superior rates of hematopoietic recovery. 1, 2 The discovery of recombinant human G-CSF and its potent effect on stem cell mobilization allows for the collection of sufficient PBSCs required for transplantation. In addition, the combination of chemotherapy before cytokine administration has been shown to significantly increase CD34+ cell (a surrogate marker for PBSCs) collection yield when compared with chemotherapy or cytokine alone, and thus a chemo-cytokine regimen is elected for mobilization when considered appropriate. [3] [4] [5] Of the several forms of recombinant G-CSF available, filgrastim is recognized as the standard with established efficacy and safety, and is recommended in evidence-based guidelines for PBSC mobilization. 6 Pegfilgrastim is a pegylated filgrastim characterized by an increased plasma half-life due to reduced renal clearance and enzymatic degradation in comparison with the non-pegylated form (T 1/2 , 33 vs 3-4 h, respectively). 7, 8 This allows for the maintenance of therapeutic serum levels of G-CSF over a period of about 14 days following a single s.c. injection of 6 mg, and is approved for the prevention of chemotherapy-induced neutropenia. 9 Such pharmacokinetic properties present pegfilgrastim as an attractive alternative to non-pegylated G-CSF for the mobilization of PBSCs as well.
Although the equivalent efficacy of a single dose of pegfilgrastim to daily G-CSF has only been established in the provision of neutrophil support, multiple experimental studies have also evaluated the use of pegfilgrastim as a part of a chemo-cytokine regimen for PBSC mobilization, particularly in multiple myeloma and lymphoma patients. [10] [11] [12] [13] More recently, comparative clinical studies of pegfilgrastim and non-pegylated G-CSF in combination with chemotherapy for PBSC mobilization in auto-HSCT patients have been performed. Although some have demonstrated that the use of pegfilgrastim results in an earlier apheresis start and reduction in the number of apheresis procedures required for PBSC collection, others have failed to show such a benefit. [14] [15] [16] Data for total CD34+ cell collection yield and neutrophil recovery rate post HSCT have been conflicting as well. 16, 17 As the literature presents inconclusive results, we performed a systematic review and meta-analysis of studies comparing PBSC mobilization outcomes of pegfilgrastim with filgrastim as part of a chemo-cytokine mobilization regimen.
MATERIALS AND METHODS

Search strategy
Clinical Oncology (ASCO), American Society of Hematology (ASH), European Society for Medical Oncology (ESMO) and European Hematology Association (EHA) were also searched between 2000 and 2014.
Selection strategy
Two authors independently evaluated articles for inclusion. The following inclusion criteria were established before literature search: the study should (i) compare outcomes in stem cell mobilization between filgrastim and pegfilgrastim and (ii) involve adult patients receiving chemo-cytokine mobilization in auto-HSCT for hematologic malignancies. Studies were excluded if they did not encompass the proper study design (non-clinical trials, reviews, case reports or case series), population (non-human, nonhematology or non-auto HSCT), intervention (not a direct comparison between agents, does not include chemotherapy in mobilization regimen, or involves additional cytokine intervention) or outcome (measures not related to cell mobilization-for example, investigates effect on neutrophil recovery, pharmacokinetics). A flow chart adapted from PRISMA was used to document the study selection process (Figure 1 ). 18 Quality assessment and data extraction Quality assessment and data extraction for the selected full-text articles were independently performed by two authors and discrepancies were resolved before data analysis. The Newcastle-Ottawa Quality Assessment Scale 19 was used to assess and assure relatively consistent quality among studies. A complete list of the data items extracted is provided in Supplementary Table 2. Study authors were contacted when there was ambiguity in the data requiring clarification. The primary outcome examined in the meta-analysis was the total CD34+ cell collection count. Secondary outcome measures included (i) day of first apheresis procedure post mobilization, (ii) number of apheresis procedures performed and (iii) day of WBC and platelet count recovery after HSCT as a measure of engraftment. Continuous outcomes extracted as median values with range were converted to mean values with s.d. by substituting median for mean and range/4 for s.d. 20 Safety outcomes were considered only for qualitative analysis.
Data analysis
The studies selected for quantitative synthesis were pooled together in a meta-analysis using both the Mantel-Haenszel fixed effects model and the DerSimonian and Laird random effects model depending on the level of heterogeneity. 21, 22 The weighted standard difference in means (SDM) and 95% confidence intervals (CI) with associated P-values were calculated for the individual studies, where Po0.05 was used as the level of significance. Heterogeneity between studies was assessed using Cochran's Q-test and quantified with Higgin's I 2 statistic. 23 When statistically significant heterogeneity was identified (Po 0.10 or I 2 440%), the random effects model was utilized to account for inter-study heterogeneity. A prespecified subgroup analysis was performed to investigate heterogeneity and to identify effects of disease diagnosis. Reporting bias detection through review of a funnel plot or additional sensitivity analysis was not performed due to the inadequate number of trials. All analyses were conducted using Comprehensive Meta-Analysis software (CMA Version 2.0; Biostat, Englewood, NJ, USA).
RESULTS
Studies included
A total of 296 studies was reviewed and nine articles fulfilled inclusion and exclusion criteria with one randomized controlled, one non-randomized controlled and seven retrospective cohort studies. In six of the seven retrospective studies, data for the treatment group (that is, pegfilgrastim) were compared against matched historical controls. One study was excluded from quantitative analysis because participants overlapped with another study. As a result, eight studies including 719 patients were analyzed in the meta-analysis. Characteristics of the final studies selected for systematic review and meta-analysis are described in Table 1 .
Total CD34+ cell collection count Total CD34+ cell collection yield was reported in all studies included in the meta-analysis with conflicting outcomes. Results presented in a forest plot (Figure 2a ) revealed no significant difference in CD34+ cell counts between the two groups (SDM: − 0.08, 95% CI: − 0.388 to 0.228; P = 0.610). Removal of an outlier study by Tricot et al. 17 reduced heterogeneity (I 2 , 49.1 vs 72.3%) but results remained non-significant. Subgroup analysis revealed a significant difference in harvest yield favoring filgrastim in lymphoma patients (SDM: − 0.354, 95% CI: − 0.619 to − 0.089; P = 0.009), but this was not detected in multiple myeloma patients (SDM: 0.014, 95% CI: − 0.414 to 0.442; P = 0.948) (Figures 2b and c) .
Day of first apheresis procedure post mobilization Day of first apheresis was investigated in six studies. Apheresis was initiated when a CD34+ cell count of ⩾ 7-20 × 10 6 cells/L or a circulating WBC count of ⩾ 4 × 10 9 cells/L was reached, as described in the study method. Pegfilgrastim mobilized groups showed an earlier apheresis onset time when compared with filgrastim in four studies, but showed no difference in two studies (Putkonen et al. 16 and Simona et al. 39 ). Pooled results showed that pegfilgrastim mobilization resulted in a significant reduction in time to first apheresis (SDM: − 0.512, 95% CI: − 0.973 to − 0.050; P = 0.030) (Figure 3a ).
Number of apheresis procedures performed
Six studies reported on the number of apheresis cycles required for collection of target CD34+ cell yield. While two studies stated that both groups required a similar number of procedures, the remaining four studies showed that the pegfilgrastim group was able to collect the target in fewer apheresis cycles. Target CD34+ cell counts ranged between a minimum of 1.5 × 10 6 cells/kg and a maximum of 7.5 × 10 6 cells/kg among studies. Meta-analysis showed that a significantly lower number of apheresis procedures was required in the pegfilgrastim group than in the filgrastim group (SDM: − 0.260; 95% CI: − 0.466 to − 0.054; P = 0.013) (Figure 3b to 0.44; P = 0.946 and SDM: 0.309, 95% CI: − 0.11 to 0.72; P = 0.145, respectively) (Figures 4a and b) .The number of cells infused for transplantation was comparable between the pegfilgrastim and filgrastim groups, without significant difference (data not shown). 6 cells/kg; pegfilgrastim vs filgrastim, respectively), pegfilgrastim mobilization resulted in an earlier leukocyte recovery rate (P = 0.004) in multiple myeloma patients, also with a reduction in heterogeneity in the subgroup analysis (22.90 vs 77.58%). The rate of platelet recovery remained non-significant despite reduced heterogeneity. A summary of subgroup analysis results is presented in Table 2 .
Safety
Five of the nine studies selected for qualitative analysis provided some description of safety outcomes. The most frequently reported adverse event associated with filgrastim and pegfilgrastim mobilization was pain. Fruehauf et al. 15 reported one patient (3.8%) with mild and reversible grade 1 thoracic pain in the pegfilgrastim group. Simona et al. 39 noted a similar ratio of mild bone pain (20%) in both groups and neither required the use of analgesics. Two episodes of bone pain (5.9% for pegfilgrastim and 6.5% for filgrastim) were reported in both groups by Ria et al. Tricot et al. 17 described grade 3 or higher bone pain requiring potent analgesics such as codeine or morphine in 5% of the patients receiving pegfilgrastim, although safety results for the filgrastim group were not presented.
A more detailed description of treatment-related adverse events was provided in the randomized study by Russell et al. 45 Bone pain was the most frequently observed adverse event with a 6.9 and 13% incidence in the pegfilgrastim and filgrastim groups, respectively. Other treatment-related adverse events including arthralgia (1.7 vs 6%), back pain (6.9 vs 3%) and headache (1.7 vs 6%) were reported for pegfilgrastim vs filgrastim. One patient (1.7%) receiving pegfilgrastim experienced an electrolyte imbalance that was considered serious and treatment-related.
DISCUSSION
This meta-analysis and systematic review summarize data available on outcomes in stem cell mobilization for pegylated vs conventional G-CSF when used in combination with chemotherapy. To our knowledge, this is the first meta-analysis to evaluate evidence comparing these cytokine agents for PBSC mobilization in patients undergoing auto-HSCT. Our pooled analysis of 719 patients showed that there was no significant difference in total CD34+ collection yield between the two agents and removal of an outlier study did not impact these results. The study by Tricot et al. 17 was considered as an outlier due to the significantly different target CD34+ count and filgrastim administration schedule. The percentage of patients who achieved target CD34+ cell collection counts, the number of CD34+ cells collected per apheresis and total blood volume processed in collection were not significantly different between the two agents (data not shown), suggesting non-inferiority of pegfilgrastim as a mobilizing cytokine. Subgroup analysis of lymphoma patients demonstrated decreased heterogeneity and favorable CD34+ yield with the use of filgrastim. Such results were most pronounced in the randomized, controlled study by Russell et al. 45 in which a large percentage of patients had received salvage therapy. This observation may reflect differences in the level of cytotoxic exposure between subgroups as auto-HSCT becomes standard of care for lymphoma patients in relapsed or refractory disease. Similarly, there have been reports of difficulty in CD34+ cell collection with the use of pegfilgrastim in heavily pretreated patients, requiring additional injections of filgrastim to aid in mobilization. 24 Pegfilgrastim mobilization resulted in a significantly earlier apheresis onset time as well as a reduction in required apheresis procedures. Bruns et al.
14 and Fruehauf et al. 15 also noted an earlier rate of leukocyte recovery following adjuvant mobilization chemotherapy in the pegfilgrastim group. These advantages in mobilization kinetics may be due to the continuously high serum levels of G-CSF maintained by pegfilgrastim. Such sustained levels are postulated to provide a more efficient stimulus to hematopoietic cells than the fluctuating levels achieved with daily filgrastim injections. [25] [26] [27] Engraftment measures post HSCT were similar between groups in the pooled analysis and one study also demonstrated comparable cell viability.
14 Previous studies have reported that successful engraftment depends primarily on the infusion of a sufficient number of CD34+ cells. 17, 28 Considering the comparable number of infused CD34+ cells between treatment groups among studies included in the meta-analysis, this suggests that the hematopoietic regenerating ability of stem cells mobilized by pegfilgrastim is similar to that of cells mobilized by filgrastim. In addition, subgroup analysis of multiple myeloma patients revealed an earlier recovery rate of leukocytes but not of platelets with pegfilgrastim use. A possible explanation could be the distinct Abbreviations: FIL = filgrastim; L = lymphoma; MM = multiple myeloma; PEG = pegfilgrastim; SDM = standard difference in means.
Pegfilgrastim vs filgrastim in mobilizationfunctional properties of pegfilgrastim vs filgrastim mobilized cells previously described in multiple myeloma patients. 29 Bruns et al.
14 have reported on the presence of a greater proportion of common myeloid, but fewer megakaryocyte-erythrocyte progenitors in pegfilgrastim mobilized cells. In our systematic review, both pegfilgrastim and filgrastim were safe and well-tolerated in mobilization. Mild and reversible bone pain was the most commonly described adverse effect at rates similar to those reported for use in neutrophil recovery after chemotherapy. [30] [31] [32] Despite previous reports of respiratory distress syndrome and splenic rupture, such adverse events were not observed in the included studies. 33, 34 Several limitations warrant caution in the interpretation of our results. A relatively small number of trials were included in our study with only one randomized controlled study, and five incorporated the use of a historical control group. Furthermore, these studies specifically selected patients who had successfully mobilized and engrafted for the control filgrastim group, and thus mobilization failure rates could not be compared. While the small sample size and nature of the study designs contribute to an increased risk of bias, the consistently high quality scores throughout studies gain validity to results of the analysis.
Significant heterogeneity was detected across studies, and thus random effects analysis was performed when appropriate. Subgroup analysis stratified by disease diagnosis decreased heterogeneity in some cases but not all suggesting other contributing sources. A number of studies have noted that advanced age, multiple cycles of prior chemotherapy and high intensity of adjuvant mobilization chemotherapy are negative prognostic factors in PBSC collection. [35] [36] [37] [38] Considerable variability was observed in the level of pretreatment and mobilization chemotherapy regimens, but additional meta-regression or subgroup analyses were not feasible due to the inadequate number of trials and unextractable information.
Another point of concern is the variable cytokine dosages used across studies. Several studies have reported sufficient mobilization of CD34+ cells with the use of a single 6 mg dose of pegilgrastim 11, 39 and a prospective comparison by Bruns et al.
14 described equal potency of pegfilgrastim 6 and 12 mg in regards to mobilization kinetics and CD34+ cell yield. Post-hoc subgroup analysis of pegfilgrastim dosages showed possibility of a dose effect on mobilization kinetics with benefits at 12 mg ( Supplementary Figures 1-5 ). Earlier apheresis start was observed for pegfilgrastim 12 mg but was not significant in the 6 mg subgroup. The reduction in the number of apheresis procedures became significant only when doses were combined (Figure 3b) . Consistent with pooled analysis, there were no differences in total CD34+ cell collection yield and day of engraftment, regardless of pegfilgrastim dose. However, the small sample size of subgroups and mixed patient population limit definitive conclusions and display the need for larger controlled studies. For filgrastim, several investigations have described the less significant influence of G-CSF dose selection in stem cell mobilization when used as a part of chemocytokine regimen 40, 41 but preselection of control groups in studies included prevent assessment of adequate dose. Future randomized, prospective studies controlling for both cytokine dosages should directly compare mobilization and engraftment outcomes to accurately evaluate appropiate dosing.
As the majority of outcomes were reported in median and range format, we utilized substitution of mean with median and s. d. with range/4. Despite arguments that these values can be significantly different when data are skewed, Hozo et al. 42 demonstrated through several simulations that in fact these substitutions may be appropriate even when data are not normally distributed. The average relative errors for mean value and s.d. were 3-10 and 9-28%, respectively (depending on sample size, minimum 8), in normal, log-normal, beta and Weibull distribution models. 42 Clinically, the long half-life of pegfilgrastim allows for a single pegfilgrastim injection compared with a median of 10 or more filgrastim injections required for optimal cell collection. 14, 39, 43, 44 In this respect pegfilgrastim may improve comfort and compliance in patients, and possibly cost-effectiveness, despite its higher unit cost. The average cost of a single 6 mg pegfilgrastim dose and 10 filgrastim injections in the United States is $5109 and $2868-$5926, respectively. 45, 46 The higher price of pegfilgrastim may be offset by a reduced number of apheresis procedures and an earlier apheresis onset leading to decreased febrile neutropenia risk, although this needs to be formally investigated in a cost-effectiveness study.
We conclude that pegfilgrastim may be a convenient alternative to filgrastim in chemo-cytokine mobilization of PBSCs for multiple myeloma and lymphoma patients undergoing auto-HSCT with advantages including an earlier apheresis start, reduction in apheresis procedures required and fewer cytokine applications. There may also be benefits in multiple myeloma patients regarding engraftment post HSCT. The optimal dose of pegfilgrastim for mobilization remains unclear and requires further investigation. Randomized studies controlling for factors including prior cytotoxic exposure, radiotherapy and select cytokine dosages should be conducted within specific patient subpopulations to evaluate their effects and confirm findings of this analysis.
